MiR-96 and miR-183 weree lower in ER+ and PR+ breast cancers than ER- and PR- breast cancers; in the meantime, their regulator, HSF2 level was lower and their target, RAB21 level, was higher in ER+ and PR+ breast cancers than ER- and PR- breast cancers (Additional file 4: Table S4). Here, ESR1 is linked to breast carcinoma.